Table 1

Patient characteristics

CharacteristicPatients
Sex, male/female, no. (%) 32/23 (58/42) 
Age at SCT, y, median (range) 44 (17-66) 
Diagnoses, no 
    ALL 
    AML 11 
    CIMF 
    CML 
    MDS 
    B-CLL 
    NHL 
    HD 
    MM 21 
    PNH 
Donor, no. (%) 
    Matched related 32 (58) 
    Mismatched related 2 (4) 
    Matched unrelated 14 (25) 
    Mismatched unrelated 7 (13) 
Conditioning, no. (%) 
    Standard 16 (29) 
    Reduced-intensity 39 (71) 
Source, PBSC/BM, no. (%) 54/1 (98/2) 
CharacteristicPatients
Sex, male/female, no. (%) 32/23 (58/42) 
Age at SCT, y, median (range) 44 (17-66) 
Diagnoses, no 
    ALL 
    AML 11 
    CIMF 
    CML 
    MDS 
    B-CLL 
    NHL 
    HD 
    MM 21 
    PNH 
Donor, no. (%) 
    Matched related 32 (58) 
    Mismatched related 2 (4) 
    Matched unrelated 14 (25) 
    Mismatched unrelated 7 (13) 
Conditioning, no. (%) 
    Standard 16 (29) 
    Reduced-intensity 39 (71) 
Source, PBSC/BM, no. (%) 54/1 (98/2) 

Summary of 55 patients with and without GVHD recruited for longitudinal CK18F measurement (for details see Table S1).

ALL indicates acute lymphoblastic leukemia; AML, acute myeloid leukemia; CIMF, chronic idiopathic myelofibrosis; CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome; NHL, non-Hodgkin lymphoma; HD, Hodgkin disease; MM, multiple myeloma; PNH, paroxysmal nocturnal hemoglobinurea; PBSC, peripheral blood stem cell; and BM, bone marrow.

Close Modal

or Create an Account

Close Modal
Close Modal